Soluble CD163 as a Potential Biomarker in Systemic Sclerosis

Current diagnostic tools for systemic sclerosis (SSc) lack specificity for early disease detection. Prior research has shown that CD163, a macrophage surface receptor, is involved in inflammation and tissue remodeling. No prior work had resolved whether soluble CD163 (sCD163) could serve as a reliable biomarker in SSc. This gap motivated researchers to evaluate serum and urinary sCD163 levels in SSc patients versus controls. Established knowledge includes the role of macrophage activation in fibrotic diseases. However, the potential of sCD163 as a diagnostic or prognostic indicator in SSc remains unexplored. This study aimed to address that uncertainty by comparing sCD163 concentrations in SSc patients and noninflammatory controls. Researchers focused on cross-sectional data to assess the feasibility of sCD163 as a biomarker. The absence of prior studies on urinary sCD163 in SSc further justified this investigation.

The study aimed to assess the potential of serum and urinary sCD163 as biomarkers in systemic sclerosis. Researchers sought to compare sCD163 levels between SSc patients and age- and sex-matched controls. The specific problem addressed was the lack of a reliable biomarker for SSc diagnosis or monitoring. Motivation stemmed from the known involvement of CD163 in macrophage signaling and inflammation. The authors proposed that sCD163 could reflect disease activity or severity in SSc. They hypothesized that elevated sCD163 levels might distinguish SSc patients from healthy individuals. The study design allowed for a direct comparison of serum and urinary concentrations. The goal was to determine which sample type showed greater promise for future research.

The study used a cross-sectional design comparing serum and urinary sCD163 levels in SSc patients and controls. Researchers collected urine and serum samples from 203 SSc patients and 47 controls with noninflammatory conditions. Sample collection followed international diagnostic guidelines for SSc. sCD163 concentrations were measured using a commercial ELISA kit. Controls were selected based on age and sex matching to reduce confounding variables. Data analysis focused on mean differences and statistical significance between groups. Clinical and laboratory characteristics of SSc patients were recorded but not linked to sCD163 levels. The study prioritized serum measurements over urinary ones for further investigation.

Serum sCD163 levels were significantly higher in SSc patients compared to controls (529 ± 251 versus 385 ± 153 ng/mL; p < 0.001). Urinary sCD163 concentrations showed a trend toward higher levels in SSc patients but did not reach statistical significance (236 ± 498 versus 176 ± 173 ng/mg uCr; p = 0.580). The difference in serum levels suggests a potential role for sCD163 as a biomarker in SSc. No associations were found between sCD163 concentrations and clinical features of SSc. The lack of correlation with disease subtypes or severity limits the diagnostic utility of sCD163. Researchers observed no distinct subset of SSc patients with elevated sCD163. The study identified serum sCD163 as a more promising sample type than urine. These findings support further exploration of serum sCD163 in larger cohorts.

The authors propose that serum sCD163 may serve as a potential biomarker in systemic sclerosis. Their findings suggest that serum measurements show greater promise than urinary ones for further research. The study supports the involvement of M2 macrophages and CD163 signaling in SSc pathogenesis. However, the authors could not identify a specific patient subgroup with elevated sCD163. The lack of association with clinical features indicates limited diagnostic utility. The study highlights the need for larger investigations to confirm these preliminary results. Researchers emphasize that serum sCD163 should be prioritized in future studies. The findings do not support the use of urinary sCD163 as a reliable biomarker.